Soleno Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

De verwachting is dat Soleno Therapeutics de winst en omzet met respectievelijk 66.8% en 77% per jaar zal laten groeien, terwijl de winst per aandeel naar verwachting zal groeien met 58.6% per jaar.

Belangrijke informatie

66.8%

Groei van de winst

58.6%

Groei van de winst per aandeel

Biotechs winstgroei	42.4%
Inkomstengroei	77.0%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	n/a

Recente toekomstige groei-updates

Geen updates

Recent updates

Winst- en omzetgroeiprognoses

BST:6XC1 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2024	37	-18	N/A	N/A	2
12/31/2023	N/A	-32	N/A	N/A	2
12/31/2022	N/A	-28	N/A	N/A	2
6/30/2022	N/A	-23	-23	-23	N/A
3/31/2022	N/A	-28	-27	-27	N/A
12/31/2021	N/A	-31	-28	-28	N/A
9/30/2021	N/A	-31	-28	-28	N/A
6/30/2021	N/A	-31	-29	-29	N/A
3/31/2021	N/A	-28	-27	-27	N/A
12/31/2020	N/A	-25	-25	-25	N/A
9/30/2020	N/A	-36	-23	-23	N/A
6/30/2020	N/A	-27	-22	-22	N/A
3/31/2020	N/A	-30	-19	-19	N/A
12/31/2019	N/A	-31	-17	-17	N/A
9/30/2019	N/A	-16	-16	-16	N/A
6/30/2019	N/A	-19	-14	-14	N/A
3/31/2019	N/A	-16	-13	-13	N/A
12/31/2018	N/A	-12	-12	-12	N/A
9/30/2018	N/A	-16	-11	-11	N/A
6/30/2018	N/A	-17	-10	-10	N/A
3/31/2018	N/A	-13	-10	-10	N/A
12/31/2017	N/A	-12	-10	-10	N/A
9/30/2017	N/A	-13	-10	-10	N/A
6/30/2017	0	-11	-11	-11	N/A
3/31/2017	0	-9	-12	-12	N/A
12/31/2016	N/A	-10	-14	-13	N/A
9/30/2016	0	-8	-14	-14	N/A
6/30/2016	0	-10	-15	-14	N/A
3/31/2016	1	-7	N/A	-12	N/A
12/31/2015	N/A	-10	N/A	-10	N/A
9/30/2015	0	-20	N/A	-8	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat 6XC1 de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat 6XC1 de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat 6XC1 de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er wordt verwacht dat 6XC1 volgend jaar geen omzet zal hebben.

Hoge groei-inkomsten: Er wordt verwacht dat 6XC1 volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van 6XC1 naar verwachting over 3 jaar hoog zal zijn

Soleno Therapeutics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Soleno Therapeutics, Inc. Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics Announces Regulatory Update on DCCR (Diazoxide Choline) Extended-Release Tablets to Treat Prader-Willi Syndrome

Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Board Changes

Soleno Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Soleno Therapeutics, Inc Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Oral Presentation featuring DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome at ENDO 2024

Soleno Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $138 million.

Soleno Therapeutics, Inc. Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS)

Soleno Therapeutics, Inc., Annual General Meeting, Jun 06, 2024

Soleno Therapeutics Strengthens Leadership Team with Key Appointments

Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Long-Term Open Label Study of DCCR in Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it has received $59.98825 million in funding

Soleno Therapeutics, Inc. announced that it expects to receive $30 million in funding

Soleno Therapeutics, Inc. Announces Positive Statistically Significant Top-Line Results from Randomized Withdrawal Period of Study C602 of Dccr for Prader-Willi Syndrome

Soleno Therapeutics Appoints Matthew Pauls to Board of Directors

Soleno Therapeutics, Inc. announced that it has received $10.000044 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome

Soleno Therapeutics, Inc. Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. announced that it expects to receive $59.89 million in funding from Abingworth LLP, Vivo Capital, LLC, Nantahala Capital Management, LLC, Brightleaf Capital, Corbin Capital Partners, L.P.

Soleno Therapeutics, Inc. Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc., Annual General Meeting, Jun 01, 2022

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Positive Data Showing Continued Significant Improvements in Symptoms of Pws Following One Year Treatment with Dccr

Soleno Therapeutics, Inc.(NasdaqCM:SLNO) dropped from Russell 3000E Growth Index

Soleno Therapeutics Receives Orphan Drug Designation from FDA for Diazoxide Choline for the Treatment of Glycogen Storage Disease Type 1A

Soleno Therapeutics Announces Presentation of Positive Behavioral Data from Ongoing Extension Study of DCCR for Treatment of Prader-Willi Syndrome

Soleno Therapeutics, Inc. Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome

New 90-day low: €1.14

Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases

Soleno Therapeutics, Inc. Provides Recap of Key Opinion Leader Webinar on DCCR for Treatment of Prader-Willi Syndrome

New 90-day high: €1.85

New 90-day high: €1.70

Soleno Therapeutics Provides Regulatory Update on Dccr for the Treatment of Prader-Willi Syndrome

Soleno Therapeutics Announces Presentation of Body Composition Results from DESTINY PWS, a Phase III Trial of DCCR in Prader-Willi Syndrome

New 90-day low: €1.35

Soleno Therapeutics, Inc. Announces the Body Composition Data from the Company’s Phase III trial, DESTINY PWS (C601)

Soleno Therapeutics, Inc. Announces Appointment of Andrew Sinclair in Board of Directors

Soleno Therapeutics Announces Updated Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven